Skip to content
Review Open access

Standard versus extended dual antiplatelet therapy after pci in acute coronary syndrome: a systematic review and meta-analysis

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

The absence of benefit was confirmed both during overall follow-up and in landmark 12-month analyses, with a reduction observed only in repeat revascularisation, a softer endpoint, and findings support an individualised approach to DAPT duration rather than routine prolongation beyond one year.

Abstract

Acute coronary syndrome (ACS) remains a major cause of cardiovascular morbidity and mortality worldwide. Following percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is routinely prescribed to prevent recurrent ischaemic events and stent thrombosis. Although guidelines generally recommend 12 months of therapy, the benefit of extending DAPT beyond one year remains uncertain because potential reductions in ischaemic events must be balanced against bleeding risk. To compare the efficacy and safety of standard-duration (≤12 months) versus extended-duration (>12 months) DAPT after PCI in adults with ACS. A systematic search of PubMed, Embase, and the Cochrane Library (inception-November 2025) identified randomised and comparative observational studies enrolling adults with ACS treated with PCI using any stent type. Studies directly comparing standard duration versus extended duration DAPT were included. Primary outcomes were myocardial infarction and clinically relevant bleeding (BARC-defined events). Secondary outcomes included mortality, major adverse cardiovascular events (MACE), stroke, target-vessel revascularisation (TVR), and definite stent thrombosis. Pooled risk ratios were calculated using random-effects models. Fourteen studies (13 cohort studies and 1 randomised trial), including 69,087 patients, were analysed. During overall follow-up, extended DAPT did not reduce myocardial infarction (RR 0.97, 95% CI 0.57–1.65), MACE (RR 0.82, 95% CI 0.52–1.31), stroke (RR 1.16, 95% CI 0.85–1.60) or definite stent thrombosis (RR 0.66, 95% CI 0.20–2.21). All-cause mortality was higher with extended therapy (RR 2.47, 95% CI 1.61–3.80). Target-vessel revascularisation was lower with standard-duration DAPT (RR 0.52, 95% CI 0.30–0.89). Bleeding risk was similar between strategies, both for any bleeding (RR 0.96, 95% CI 0.72–1.28) and clinically relevant bleeding (BARC 2/3/5 RR 1.07, 95% CI 0.78–1.49). In a landmark analysis at 12 months, extended DAPT did not reduce myocardial infarction (RR 0.57, 95% CI 0.12–2.62), MACE (RR 0.65, 95% CI 0.25–1.68), definite stent thrombosis (RR 0.55, 95% CI 0.11–2.79), cardiac death (RR 2.24, 95% CI 1.00–5.00) or all-cause mortality (RR 1.85, 95% CI 0.68–5.03), nor increase clinically relevant bleeding (BARC 2/3/5 RR 0.98, 95% CI 0.55–1.77). In patients with ACS undergoing PCI, extending dual antiplatelet therapy beyond 12 months does not provide consistent reductions in major ischaemic outcomes, including myocardial infarction, stent thrombosis, or mortality. The absence of benefit was confirmed both during overall follow-up and in landmark 12-month analyses, with a reduction observed only in repeat revascularisation, a softer endpoint. These findings support an individualised approach to DAPT duration rather than routine prolongation beyond one year. Further adequately powered randomised trials are needed.OUTCOMESCENTRAL ILLUSTRATION

Read PDF

Similar papers

Review Open access Oct 2026

Comparative efficacy of clopidogrel and aspirin monotherapy after dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

Optimal long-term antiplatelet monotherapy following percutaneous coronary intervention (PCI) remains debated, with aspirin traditionally recommended despite emerging evidence supporting P2Y12 inhibitor monotherapy. The comparison of clinical outcomes between clopidogrel and aspirin monotherapy in patients...

N. Ktenopoulos, K. Karampinos, A. Apostolos et al. · 0 citations
Review Oct 2026

Extended Versus Short Dual Antiplatelet Therapy Duration After Percutaneous Coronary Intervention for Chronic Total Occlusion: A Systematic Review and Meta-Analysis.

Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with substantial ischemic risk, yet the optimal duration of dual antiplatelet therapy (DAPT) after successful CTO-PCI remains uncertain. We conducted a systematic review and meta-analysis comparing extended DAPT (>12 months) with short...

A. Emara, A. Mansour, Ahmed Wahdan Kasem et al. · 0 citations
Review Open access Oct 2026

Efficacy and safety of short (≤6 months) versus prolonged (>6 months) dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis

The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains uncertain, as therapy must balance ischemic protection against bleeding risk. While prolonged DAPT may enhance antithrombotic efficacy, shorter regimens have been proposed to improve safety. To c...

A. Gasca, N. Nelson, A. Beltran et al. · 0 citations
Review Open access Oct 2026

Antiplatelet monotherapy maintenance strategies after percutaneous coronary intervention in patients with coronary artery disease at high bleeding risk: a network meta-analysis

Background The optimal antiplatelet monotherapy maintenance strategy after percutaneous coronary intervention (PCI) remains uncertain in patients with coronary artery disease at high bleeding risk, particularly among those not receiving oral anticoagulant therapy. We performed a network meta-analysis to compare the saf...

Xiao Zhang, Yu-Jie Wang, Y. Guo et al. · 0 citations
Open access Oct 2026

Clopidogrel or prasugrel vs. aspirin monotherapy for long-term secondary prevention after percutaneous coronary intervention for acute coronary syndrome

Optimal long-term antiplatelet monotherapy in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) remains a subject of ongoing debate. In particular, it remains unclear whether different P2Y12 inhibitors provide comparable clinical benefits when used as long-term mon...

Y. Iwanaga, K. Kanaoka, K. Takegawa et al. · 0 citations
Open access Oct 2026

Ticagrelor versus prasugrel following PCI in acute coronary syndromes and high-risk coronary artery disease: A meta-analysis of one-year randomized trial outcomes

Background Guidelines recommend potent P2Y12 inhibitors over clopidogrel following percutaneous coronary intervention. Whether ticagrelor- or prasugrel-based dual antiplatelet therapy (DAPT) provides superior clinical outcomes following percutaneous coronary intervention (PCI) remains uncertain, particularly across acu...

M. Gbreel, A. Badran, Daniel Robinson et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.